Skip to main content

Table 2 The results of univariate analysis

From: Eosinophil-to-monocyte ratio is a potential biomarker in the prediction of functional outcome among patients with acute ischemic stroke

Characteristics

Poor outcome

p value

No

Yes

Age, years, mean (SD)

66.90 ± 12.68

74.17 ± 13.09

< 0.001

Female, (%)

140 (41.18%)

92 (50.83%)

0.035

Hypertension, (%)

285 (83.82%)

160 (88.40%)

0.159

Diabetes, (%)

77 (22.65%)

50 (27.62%)

0.208

Hyperlipidemia, (%)

147 (43.24%)

62 (34.25%)

0.046

Previous stroke, (%)

49 (14.41%)

47 (25.97%)

0.001

Coronary heart disease, (%)

20 (5.88%)

31 (17.13%)

< 0.001

Atrial fibrillation, (%)

29 (8.53%)

57 (31.49%)

< 0.001

Current cigarette smoking, (%)

33 (9.71%)

21 (11.60%)

0.499

NIHSS, median (IQR)

2 (1–3)

7.00 (4–11)

< 0.001

Premorbid mRS score, median (IQR)

0 (0–0)

0 (0–0)

0.065

Stroke subtypes

< 0.001

 Large artery atherosclerosis

108 (31.76%)

80 (44.20%)

 

 Cardioembolic stroke

25 (7.35%)

52 (28.73%)

 

 Small artery disease

201 (59.12%)

49 (27.07%)

 

 Other etiology/unknown

6 (1.76%)

0 (0.00%)

 

IV rtPA, (%)

29 (8.53%)

16 (8.84%)

0.904

Proton pump inhibitors

106 (31.18%)

107 (59.12%)

< 0.001

Triglyceride, mmol/L, median (IQR)

1.46 (1.02–2.03)

1.21 (0.94–1.67)

0.001

Total cholesterol, mmol/L, mean (SD)

4.91 ± 1.45

4.94 ± 1.15

0.765

High-density lipoprotein cholesterol, mmol/L, mean (SD)

1.29 ± 0.37

1.33 ± 0.38

0.289

Low-density lipoprotein cholesterol, mmol/L, mean (SD)

2.46 ± 0.74

2.50 ± 0.74

0.577

EMR, median (IQR)

0.22 (0.10–0.39)

0.12 (0.05–0.23)

< 0.001

  1. EMR eosinophil-to-monocyte ratio, IQR interquartile range, IV rtPA intravenous recombinant tissue plasminogen activator, NIHSS National Institutes of Health Stroke Scale